Underrepresentation of minorities in clinical trials is a dangerous problem, as safe and effective treatments for all are only possible
if there is patient diversity in the clinical trials of those treatments. Fortunately, this issue is receiving more attention from the healthcare
community and technologies exist to enable more equitable access to care. In this G3 Meets episode, Dr. Otis Johnson, Chief Diversity, Inclusion & Sustainability Officer at Clario, discusses the lack of diversity in clinical trials, the connection between patient and workforce diversity, and what is being done to foster greater diversity in future trials.